We are live on ! Find out more
PPH icon

VanEck Pharmaceutical ETF
PPH

52 hedge funds and large institutions have $113M invested in VanEck Pharmaceutical ETF in 2018 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 14 increasing their positions, 13 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 3

21% more capital invested

Capital invested by funds: $93M → $113M (+$19.6M)

12.79% more ownership

Funds ownership: 33.43% → 46.22% (+13%)

4% more funds holding

Funds holding: 50 → 52 (+2)

8% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 13

75% less call options, than puts

Call options by funds: $408K | Put options by funds: $1.65M

Holders
52
Holders Change
+2
Holders Change %
+4%
% of All Funds
1.19%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
14
Reduced
13
Closed
3
Calls
$408K
Puts
$1.65M
Net Calls
-$1.24M
Net Calls Change
-$904K

Top Buyers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
+$23.9M
2
Bank of America
Bank of America
North Carolina
+$3.8M
3
SG Americas Securities
SG Americas Securities
New York
+$2.77M
4
ECM
Endurant Capital Management
California
+$1.52M
5
CCT
Country Club Trust
Missouri
+$937K

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$4.79M
2
Morgan Stanley
Morgan Stanley
New York
-$1.81M
3
TRCT
Tower Research Capital (TRC)
New York
-$723K
4
Creative Planning
Creative Planning
Kansas
-$706K
5
MIH
Meitav Investment House
Israel
-$589K
Name Holding Trade Value Shares
Change 		Change in
Stake
RJFSA
26
Raymond James Financial Services Advisors
Florida
$240K -$99.9K -1,672 -28%
FPCM
27
Financial Partners Capital Management
New York
$223K – – –
KFC
28
Klingenstein Fields & Co
New York
$216K – – –
Bank of Montreal
29
Bank of Montreal
Ontario, Canada
$165K – – –
NSIM
30
North Star Investment Management
Illinois
$154K +$132K +2,202 +438%
FDCDDQ
31
Federation des caisses Desjardins du Quebec
Quebec, Canada
$136K – – –
LTFS
32
Ladenburg Thalmann Financial Services
Florida
$119K -$40.3K -675 -24%
JP Morgan Chase
33
JP Morgan Chase
New York
$111K – – –
AG
34
Advisor Group
Arizona
$83K – – –
NL
35
NVWM LLC
Pennsylvania
$82K +$11.4K +190 +14%
TCM
36
Tradewinds Capital Management
Washington
$68K – – –
APP
37
Avantax Planning Partners
Iowa
$63K +$66.5K +1,113 New
GT
38
Glenmede Trust
Pennsylvania
$59K – – –
ASN
39
Advisory Services Network
Georgia
$44K -$5.92K -99 -11%
MIM
40
Macroview Investment Management
Maryland
$43K +$60 +1 +0.1%
HCM
41
Highlander Capital Management
New Jersey
$41K – – –
JCM
42
Jacobi Capital Management
Pennsylvania
$24K – – –
Carson Wealth (CWM LLC)
43
Carson Wealth (CWM LLC)
Nebraska
$23K – – –
WWM
44
Willingdon Wealth Management
North Carolina
$19K – – –
CPA
45
Clear Perspective Advisors
Illinois
$17K – – –
William Blair & Company
46
William Blair & Company
Illinois
$11K +$11.7K +195 New
ADL
47
Asset Dedication LLC
California
$10K – – –
IA
48
IFP Advisors
Florida
$9K – – –
FANJ
49
Financial Architects (New Jersey)
New Jersey
$4K +$60 +1 +1%
AIM
50
Anchor Investment Management
South Carolina
$3.3K – – –
1
2
3

PPH Hedge Fund Activity: Q1 2018 in Review

52 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in VanEck Pharmaceutical ETF (PPH) for Q1 2018, worth a combined $113M — up 21% from $93M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new PPH positions and 3 closed out — a net gain of 2 holders — while 14 added to existing stakes and 13 trimmed.

The largest buyer was Goldman Sachs, adding an estimated $23.9M. The largest seller was UBS Group, cutting an estimated $4.79M.

  • 52 institutional investors held VanEck Pharmaceutical ETF (PPH) as of Q1 2018, up from 50 in Q4 2017.
  • Funds reported $113M of VanEck Pharmaceutical ETF stock for Q1 2018, up 21% quarter-over-quarter.
  • 5 funds opened new VanEck Pharmaceutical ETF positions in Q1 2018 and 3 closed out, a net change of +2 holders.
  • The largest VanEck Pharmaceutical ETF buyer in Q1 2018 was Goldman Sachs, an estimated $23.9M added.
  • The largest VanEck Pharmaceutical ETF seller in Q1 2018 was UBS Group, an estimated $4.79M sold.

Based on aggregated 13F filings for Q1 2018.